Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2016

View Archived Issues

Novel IRAK-4 kinase inhibitor shows promise for cancer and inflammatory diseases

Humabs Biomed describes novel monoclonal antibody for treating hepatitis B virus infection

Regen Biopharma enters agreement for HemaXellerate trial

Strekin begins phase II study of STR-001

Advaxis' ADXS-HER2 gains FDA fast track status

Laninamivir octanoate effective and well tolerated as post-exposure prophylaxis for influenza

NVR-3-778 well tolerated and reduces HBV DNA in phase Ib trial

Janssen submits NDA to FDA seeking approval of mebendazole chewable tablet

AbbVie acquires Stemcentrx and its late-stage Rova-T compound

Yuhan patents HER1 inhibitors

Calitor Sciences and Sunshine Lake Pharma disclose protein kinase inhibitors

Boehringer Ingelheim Pharma develops aldosterone synthase inhibitors

Kineta divulges antivirals

GSK reflects on milestones of first quarter 2016

Helix enrolling patients in phase II portion of phase I/II trial of L-DOS47 in NSCLC

Color Genomics launches Color Test for hereditary cancers

Abbott set to acquire St. Jude Medical

Novel genetic variant may cause mitochondrial diseases

ChemoCentryx awarded grant for development of CCX-168

Arrowhead Pharmaceuticals files for approval of phase I/II study of ARC-521 in New Zealand

FDA approves AstraZeneca's Bevespi Aerosphere for COPD

NIH grant supports Scripps' investigation of role of microRNAs in physiological activities

Galapagos and AbbVie expand collaboration in cystic fibrosis

Alkermes reports on phase I study of ALKS-7119

FDA gives fast track designation to Therabron Therapeutics's rhCC10

Adamas Pharmaceuticals reports positive results from EASE LID 3 study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 12, 2025.
Deep Apple signs big Novo deal for cardiometabolic small molecules
BioWorld
Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
23andme genetic privacy concerns garner Congressional scrutiny
BioWorld MedTech
The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race
BioWorld
3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...